This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]
Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer’s disease
Matsuda, Osamu,
Shido, Emi,
Hashikai, Ayako,
Shibuya, Haruka,
Kouno, Mitsue,
Hara, Chizuko,
Saito, Masahiko
Background: Acetylcholinesterase inhibitors (i.e. donepezil) are known to benefit Alzheimer’s disease (AD) patients. However, the combined effects of acetylcholinesterase and cognitive stimulation therapy (CST) are still debated. The present study examined their combined effects on the progression of cognitive decline in AD.; Methods: The present study was a non-randomized controlled study and included two groups […]
Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)
Objective: To evaluate, in a real-world clinical setting, the efficacy of rivastigmine in the management of six symptoms commonly associated with Alzheimer’s disease (AD).; Methods: This was a naturalistic, prospective, open-label, multi-centre, post-marketing, observational study. Data were collected by the participating study physicians at their practices across Canada. Subjects had a clinical diagnosis of mild-to-moderate […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]
Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia
Liu, Xuan,
Zhang, Junjian,
Sun, Dong,
Fan, Yuanteng,
Zhou, Hongbin,
Fu, Binfang
Background: Selective serotonin reuptake inhibitors improve cognition in patients with stroke and increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. However, the effects of selective serotonin reuptake inhibitors on cognition and serum BDNF levels in patients with vascular dementia are largely unknown. We performed an open-label study to investigate the effects […]
An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer’s Disease
Guo, Qihao,
Zhou, Yan,
Wang, Chao-Jih,
Huang, Young-Ming,
Lee, Yi-Ta,
Su, Muh-Hwan,
Lu, Jiahong
Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed […]